Researchers at the University of Maryland, Baltimore County have identified how enteroviruses, a family that includes polio and rhinovirus (common cold), hijack human cells to reproduce. The discovery targets the viral RNA's ability to recruit both viral and host proteins into a replication complex, functioning like a molecular switch that determines whether the virus copies its genome or manufactures viral proteins.
The team captured this mechanism at atomic resolution using cryo-electron microscopy and other structural biology techniques. Enteroviruses infect hundreds of millions of people annually and cause diseases ranging from mild respiratory illness to severe conditions like myocarditis and encephalitis. Understanding their replication strategy opens pathways for antiviral drug development.
The research reveals that viral RNA acts as a scaffold, bringing together the viral RNA-dependent RNA polymerase and host cell factors in a precise arrangement. This assembly controls the switch between two critical phases: the replication phase, where viral RNA copies itself, and the protein synthesis phase, where the cell machinery translates viral genetic material into new viral proteins. By mapping this molecular switching mechanism, scientists identified a potential vulnerability in the viral lifecycle.
The significance lies in creating a rational basis for designing drugs that could disrupt this switch. Current antiviral options for enteroviruses remain limited. A compound that blocks the recruitment of host proteins or destabilizes the replication complex could theoretically prevent viral replication without harming uninfected cells.
However, limitations exist. The structure captured represents a snapshot of one state in a dynamic process. The complexity of translating structural findings into effective drugs typically requires years of additional research. Additionally, the diversity of enteroviruses means blocking one mechanism might not work uniformly across all species. Viral resistance could emerge if the virus mutates its RNA binding sites.
The work represents foundational knowledge that informs but does not guarantee therapeutic breakthroughs. Researchers